A team at the Wellcome Trust Sanger Institute has discovered how a promising malarial vaccine target - the protein RH5 - helps parasites to invade human red blood cells.
Published in Nature Communications, the study reveals that a previously mysterious protein on the surface of the parasite called P113 anchors the RH5 protein, and provides a molecular bridge between the parasite and a red blood cell. The discovery could be used to make a more effective malaria vaccine.
More than 200 million people a year are infected with malaria and the disease caused the deaths of nearly half a million people worldwide in 2015. Children under the age of five made up 70 percent of these deaths. Malaria is caused by Plasmodium parasites which are spread by infected mosquitos and an effective vaccine would vastly improve the lives of millions of people.
Previous research by teams at the Sanger Institute discovered that to invade human red blood cells, Plasmodium parasites need RH5 to bind to a receptor called basigin on the surface of the blood cells.
However, it was not known how RH5 was attached to the surface of the parasite. In this latest study the researchers discovered that when the Plasmodium RH5 proteinis released, it is immediately caught by another parasite protein called P113. Thousands of P113 molecules on the surface of each parasite act like a Velcro chain, capturing RH5 at the surface of the parasite.
The tethered RH5 then binds to the basigin receptor on the human red blood cell, bridging the gap just long enough to let the parasite invade the blood cell. Dr Julian Rayner, an author on the study from the Sanger Institute, said: "We knew both proteins were essential for invasion but this is the first time anyone has seen the interaction between RH5 and P113 and showed that they work together.
In theory, an antibody that blocked P113 could stop RH5 binding and so prevent the parasite from gaining entry to red blood cells. This makes the P113 protein another good vaccine target."